

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
6 December 2001 (06.12.2001)

PCT

(10) International Publication Number  
**WO 01/91801 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 48/00**,  
C12N 15/867, A61P 25/28, 25/14, 25/16

(21) International Application Number: PCT/US01/17209

(22) International Filing Date: 25 May 2001 (25.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/207,541 26 May 2000 (26.05.2000) US  
60/279,035 27 March 2001 (27.03.2001) US

(71) Applicants (for all designated States except US): **CHIRON CORPORATION** [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US). **UNIVERSITY OF IOWA RESEARCH FOUNDATION** [US/US]; 100 Oakdale Campus, #214 TIC, Iowa City, IA 52240 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DAVIDSON, Beverly, L.** [US/US]; 3640 Johnston Way, N.E., North Liberty, IA 52317 (US). **ALISKY, Joseph, M.** [US/US]; 35

Valley Avenue, Apartment 8, Iowa City, IA 52242 (US). **DUBENSKY, Thomas, W., Jr.** [US/US]; 6 Pacific Avenue, Piedmont, CA 94611 (US). **HUGHES, Stephanie, M.** [NZ/US]; 182 Westside Drive, Apartment 8, Iowa City, IA 52246 (US). **JOLLY, Douglas** [GB/US]; 382 Sunset Drive, Encinitas, CA 92024 (US). **SAUTER, Sybille, L.** [DE/US]; 639 Stratford Court, #17, Del Mar, CA 92014 (US).

(74) Agents: **DOLLARD, Anne**; Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA 94662 et al. (US).

(81) Designated States (*national*): CA, JP, US.

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).


**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS OF TRANSDUCING NEURAL CELLS USING LENTIVIRUS VECTORS

(57) Abstract: Gene delivery vectors, such as, for example, recombinant FTV vectors, and methods of using such vectors are provided for use in transducing neural cells, such as neural progenitor cells, and cerebellar neurons, in particular, Purkinje cells.



**WO 01/91801 A2**

5     METHODS OF TRANSDUCING NEURAL CELLS USING LENTIVIRUS VECTORS

Technical Field

      The present invention relates to methods for transducing neural cells and methods  
for treating diseases of the central nervous system. In particular, the present invention  
10    pertains to the use of various gene delivery vectors which direct the expression of  
selected gene products in neural progenitor cells and/or cerebellar neurons.

Background Of The Invention

      Degenerative diseases of the cerebellum are potentially amenable to gene therapy  
15    if transduction to sufficient numbers of neurons can be achieved. For example, some of  
the autosomal dominant spinocerebellar ataxias (SCA) are due to loss of Purkinje cells,  
inferior olivary and pontine neurons, and to a lesser extent granule cells (Kato et al., *Acta*  
*Neuropathol* 96:67-74, 1998; Koeppen, A.H., *J Neuropath and Experimental Neurology*  
57:531-543, 1998). Onset is typically from the fifth to seventh decade of life, with  
20    degeneration occurring over a decade. The underlying genetic defect in several types of  
the SCA (SCA-1, SCA-2, SCA-3, SCA-6, and SCA-7) causes polyglutamine tract  
expansion and a toxic gain of function in the encoded protein (Klockgether and Evert,  
*Trends Neurosci* 21:413-418, 1998; Paulson et al., *Am J Hum Genet* 64:339-345, 1999).

      Neural progenitor or stem cells are a potential target for neurodegenerative disease  
25    therapy. Progenitor cells may be used to replace neural cell types, neurons, astrocytes or  
oligodendrocytes and to act as a vector for delivery of therapeutic molecules to the  
degenerating CNS. Delivery of therapeutic gene products or differentiation cues would  
be enhanced by viral-mediated gene delivery however, the effects of viral-mediated gene  
transfer on primary neural progenitor cells have not heretofore been well characterized.

Neural progenitor cells are found in the CNS throughout life. In the adult, neurogenesis is maintained in the ventricular region (Altman, J., *J.Comp.Neurol.* 137:433-458, 1969; Corotto et al., *Neurosci.Lett.* 149:111-114, 1993) where precursor cells migrate through the rostral migratory stream to the olfactory bulb, differentiating  
5 into granule and periglomerular neurons (Altman, J., *J.Comp.Neurol.* 137:433-458, 1969; Lois et al., *Science* 264:1145-11483, 1994). Granule neurons also continue to differentiate from progenitors in the subgranular zone of the dentate gyrus (Altman et al., *J.Comp.Neurol.* 124:319-336, 1965).

Neural progenitor cells can be isolated from either embryonic or adult brain and  
10 maintained in culture either as primary cultures or immortalized cell lines (Reynolds et al. *Science* 255:1707-1710, 1992; Reynolds et al., *J. Neurosci.* 12:4565-4574, 1992; Snyder et al., *Cell* 68:33-51, 1992). In primary culture, nestin-positive progenitor cells are cultured in the presence of epidermal and/or basic fibroblast growth factors generating clones of progenitor cells commonly referred to as neurospheres (Reynolds et al. *Science*  
15 255:1707-1710, 1992; Gage et al., *PNAS* 92:11879-11883, 1995), which with removal of mitogens, will differentiate into all major neural cell types (Reynolds et al. *Science* 255:1707-1710, 1992; Reynolds et al., *J.Neurosci.* 12:4565-4574, 1992).

Progenitor cells immortalized by retroviral-mediated v-myc gene transfer have been used for cell replacement and delivery of secreted gene products. Over expression  
20 of *Nurr-1*, required for induction of dopaminergic phenotype, in the murine cerebellar progenitor cell line C17.2 (Snyder et al., *Cell* 68:33-51, 1992) resulted in differentiation of progenitors into TH-positive neurons in the presence of type-1 astrocytes (Wagner et al., *Nat Biotechnol* 17:653-659, 1999). The delivery of  $\beta$ -glucuronidase to newborn MPS VII mice using modified C17.2 cells showed that these cells can secrete gene products  
25 and correct lysosomal pathology (Snyder et al., *Nature* 374:367-370, 1995). Migration of implanted immortalized or primary neural progenitor cells is enhanced in the setting of CNS injury. For example, progenitor cells migrate towards tumors (Benedetti et al., *Nat.Med.* 6:447-450, 2000; Herrlinger et al., *Mol.Ther.* 1:347-357) or apoptotic areas (Snyder et al., *PNAS* 94:11663-11668, 1997).

Previous investigations of gene transfer in the cerebellum has examined replication-deficient adenovirus vectors (rAd). Adenoviruses are non-integrating, non-enveloped DNA viruses. rAd expressing  $\beta$ -galactosidase injected into the cerebellar cortex of mice transduced numerous precerebellar neurons in the brainstem (Terashima et al., *Anat Embryol* 196:363-382, 1997). This occurred via retrograde axonal transport of virions from mossy fiber terminals in the cortex back to neuronal soma. However, within the cortex itself mainly glia were transduced, with only minimal transfection of Purkinje cells or other classes of neurons. Viral vectors that transduce cerebellar neurons would be preferable in the study of the spinal cerebellar ataxias, and for testing therapies in representative animal models (Vig et al., *J Neurol Sci* 174:100-110, 2000; Lorenzetti et al., *Hum Mol Genet* 9:779-785, 2000).

Recombinant adenoassociated viruses (rAAV) have been shown to mediate gene transfer to neurons when injected into the rodent cerebrum (During et al., *Gene Therapy* 5:820-827, 1998; Davidson et al., *PNAS* 97:3428-3432, 2000). AAVs are DNA dependoviruses, and require adenovirus or herpesvirus as helper for productive infections. Earlier studies showed that vectors derived from AAV2 efficiently transduce neurons immediate to the site of administration in the hippocampus and inferior colliculi of rats (Bartlett et al., *Hum Gene Ther* 9:1181-1186, 1998; Davidson et al., *PNAS* 97:3428-3432, 2000). More recently, rAAV5-based vectors have been shown to be capable of diffusion within the mouse striatum well beyond the injection site (Davidson et al., *PNAS* 97:3428-3432, 2000). Similar to rAAV2 vectors, rAAV5 vectors predominantly transduced neurons in the hippocampus, cortex, striatum or medial septum.

Recombinant retroviral gene delivery methods have been extensively utilized in gene therapy approaches, in part due to: (1) the efficient entry of genetic material (the vector genome) into cells; (2) an active, efficient process of entry into the target cell nucleus; (3) relatively high levels of gene expression; (4) the potential to target particular cellular subtypes through control of the vector-target cell binding and the tissue-specific control of gene expression; (5) a general lack of pre-existing host immunity; (6) substantial knowledge and clinical experience which has been gained with such vectors; and (7) the capacity for stable and long-term expression.

Briefly, retroviruses are diploid positive-strand RNA viruses that replicate through an integrated DNA intermediate. Upon infection by the RNA virus, the retroviral genome is reverse-transcribed into DNA by a virally encoded reverse transcriptase that is carried as a protein in each retrovirus. The viral DNA is then integrated pseudo-randomly into the host cell genome of the infected cell, forming a "provirus" which is inherited by daughter cells.

One type of retrovirus, the murine leukemia virus, or "MLV", has been widely utilized for gene therapy applications (see generally Mann et al. *Cell* 33:153, 1983; Cane and Mulligan, *PNAS* 81:6349, 1984; and Miller et al., *Human Gene Therapy* 1:5-14, 1990). One major disadvantage of MLV-based vectors, however, is that the host range (i.e., cells infected with the vector) is limited, and the frequency of transduction of non-replicating cells is generally low.

Adenovirus and AAV, as well as lentivirus, can infect terminally differentiated cells without the need for cell division, and have thus been used for gene transfer to the CNS where cell division is limited (Davidson et al., *Nat. Genet.* 3:219-223, 1993; Mastrangeli et al., *Clin. Res.* 41:223A(Abstract), 1993; Ghadge et al., *Gene Ther.* 2:132-137, 1995; Xiao et al., *Exp. Neurol.* 144:113-124, 1997; McCown et al., *Brain Res.* 713:99-107, 1996; Chamberlin et al., *Brain Res.* 793:169-175, 1998; Blömer et al., *J. Virol.* 71:6641-6649, 1997; Zufferey et al., *Nat Biotechnol* 15:871-875, 1997; Kordower et al., *Exp. Neurol.* 160:1-16, 1999). Feline immunodeficiency virus ("FIV") is an RNA virus of the lentivirus family that infects both dividing and non-dividing cells and integrates into the host genome, allowing transgene maintenance in dividing cells. FIV-mediated gene therapy vector systems have also been described (see, International Publication Nos. WO 99/15641 and WO 99/36511).

Replication incompetent recombinant lentiviral vectors derived from human immunodeficiency virus (rHIV) and rFIV show tropism for neurons *in vitro* (Poeschla et al., *Nat Med* 4:354-357, 1998) and *in vivo* when injected into the cerebrum (*Science* 272:263-267, 1996; Naldini, *J. Virol.* 1996). The recombinant lentivirus vectors remain capable of infecting non-dividing cells when deleted of accessory proteins (Johnston et al., *J Virol* 73:4991-5000, 1999, Naldini, *Throm Haemat* 82:552-554, 1999). In recent

studies, rHIV vectors pseudotyped with the vesicular stomatitis glycoprotein G (VSV-g) envelope protein mediated gene transfer to a large number of striatal neurons when injected into non-human primate brain, with no apparent decline in transgene expression throughout the three month study (Kordower et al., *Exp Neurol* 160:1-16, 1999).

5 Similar results have been found with lentivirus vectors based on FIV. Such vectors have also been shown to be effective in infecting hematopoietic stem cells. (An et al., *J. Virol.* 74:1286-1295, 2000; Sutton et al., *J. Virol.* 73:3649-3660, 1999; Uchida et al., *PNAS* 95:11939-11944, 1998; Case et al., *PNAS* 96:2988-2993, 1999; Miyoshi et al., *Science* 283:682-686, 1999; Evans et al., *Hum. Gene Ther.* 19:1479-1489, 1999). However, 10 lentiviral infection of primary neural progenitor cells has not previously been reported.

The present invention provides methods for transducing neural progenitor cells and cerebellar neurons, as well as methods for treating and preventing a number of diseases associated with the central nervous system and cerebellar degeneration, using retrovirus-mediated gene transfer and, further, provides other related advantages.

#### Summary of the Invention

The present invention provides methods for transducing neural cells, including neural progenitor cells and cerebellar neurons. The methods are useful for studying CNS and cerebellar disorders, and for testing therapies in representative animal models. The 20 invention also provides methods for treating, preventing, or inhibiting diseases of the brain and other disorders of the central nervous system (CNS), such as but not limited to, Parkinson's, multiple sclerosis, Alzheimer's, and other diseases that cause cerebellar degeneration. Transduced progenitor cells may be used to replace neural cell types, neurons, astrocytes and/or oligodendrocytes and therefore to deliver therapeutic 25 molecules to degenerating CNS.

In particular, it has been surprisingly found that cerebellar neurons and neural progenitor cells can be effectively transduced using FIV vectors. Nestin-positive neurospheres can be regenerated from single FIV-infected progenitors, indicating that FIV infection does not inhibit progenitor cell self-renewal. FIV-infected progenitors also 30 retain the potential for differentiation, such as into neurons and glia.

Thus, within one aspect of the present invention, methods are provided for treating or preventing diseases of the CNS and/or cerebellum comprising the step of direct introduction to the CNS or cerebellum a gene delivery vector which directs the expression of one or more polypeptides, proteins or enzymes, such that the disease is treated or prevented. Within certain embodiments of the invention, a viral promoter (e.g., CMV), a tissue-specific promoter (e.g., opsin, RPE, cholecystokinin (see, U.S. Patent No. 5,681,744) and neuropeptide Y promoter), or an inducible promoter (e.g., tet) is utilized to drive the expression of the polypeptide, protein or enzyme factor.

According to a preferred embodiment, the invention provides a method of transducing neural progenitor cells, or Purkinje cells of the cerebellum.

Preferred gene delivery vectors suitable for use with the present invention may be generated from retroviruses such as FIV or HIV. In a particularly preferred embodiment, the gene delivery vector is an FIV vector.

Utilizing the methods and gene delivery vectors provided herein a wide variety of CNS and cerebellar diseases and disorders may be readily treated or prevented, including for example, spinocerebellar ataxias (SCA) such as SCA-1, SCA-2, SCA-3, SCA-6, and SCA-7; cerebellar degeneration due to alcoholism; idiopathic Purkinje cell degeneration; lithium intoxication; ceroid lipofuscinosis; ataxia telangiectasia; high dose arabinoside; Huntington's disease; fragile X syndrome; hereditary motor and sensory neuropathy and cerebellar atrophy; Alzheimer's disease (both sporadic and familial); normal aging; Parkinson's Disease and Parkinson's disease-like symptoms such as muscle tremors, muscle weakness, rigidity, bradykinesia, alterations in posture and equilibrium and dementia; demyelinating diseases such as, but not limited to, multiple sclerosis, parainfectious disorders such as acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalopathy, viral infections such as progressive multifocal leukoencephalopathy and subacute sclerosing panencephalitis, nutritional disorders such as vitamin B<sub>12</sub> deficiency, demyelination of the corpus callosum (Marchiafava-Bignami disease) and central pontine myelinolysis, anoxic-ischemic sequelae such as delayed postanoxic cerebral demyelination and progressive subcortical ischemic encephalopathy; demyelinating diseases such as, but not limited to, the leukocystrophies such as

metachromatic leukodystrophy, sudanophilic (Pelizaeus-Merzbacher disease), globoid cell (Krabbe's disease), adrenoleukodystrophy (Schilder's disease), Alexander's disease, Canavan's disease, Seitelberger's disease, aminoacidurias; multisystem atrophy; paraneoplastic Purkinje cell degeneration; metachromatic leukodystrophy (enzyme-deficient and activator-deficient form); manic depression; bipolar disorders; schizophrenia; autism; traumatic brain and spinal cord injury, and the like.

Accordingly, the methods of the present invention may be used to alleviate abnormalities of the CNS and cerebellum that result in demyelination, dysmyelination, dementia, dysmetria, ataxia, past pointing, dysidiadochokinesia, dysarthria, intention and action tremor, cerebellar nystagmus, rebound, hypotonia, and loss of equilibrium.

Genes encoding a wide variety of polypeptides, proteins or enzymes may be employed, including those which, when expressed, prevent or alleviate the effects of the particular CNS and/or cerebellar disorder in question. Examples of such proteins include, but are not limited to CLN2 (tripeptidyl protease; ttp); CLN3; CLN1 (protein palmitoyl thioesterase); calbindin; glutamate decarboxylase; the genes encoding proteins deficient in SCA-1, SCA-2, SCA-3, SCA-6, and SCA-7; ataxin (1-7); arylsulfatase A, sulfatide activator/saposin; galactosylceramidase; various growth factors such as any of the various NGFs and FGFs, as well as CNTF, BDNF, GDNF, NT3, NT4/5, and IGF-1; monoamine oxidase; tyrosine hydroxylase; the Huntington (htt) gene; bipolar genes such as G-protein alpha subunit gene and Galphaz (GNAZ); serotonin transporter gene; serotonin receptor HTR-7, genes in the VCSF region of chromosome 22; and anti-apoptotic genes. Moreover, critical enzymes involved in the synthesis of neurotransmitters such as dopamine, norepinephrine, and GABA have been cloned and available and can be used to treat a broad range of brain disease in which disturbed neurotransmitter function plays a crucial role, such as schizophrenia, manic-depressive illnesses and Parkinson's Disease. It is well established that patients with Parkinson's suffer from progressively disabled motor control due to the lack of dopamine synthesis within the basal ganglia. The rate limiting step for dopamine synthesis is the conversion of tyrosine to L-DOPA by the enzyme, tyrosine hydroxylase. L-DOPA is then converted to dopamine by the ubiquitous enzyme, DOPA decarboxylase. Thus, the



genes for tyrosine hydroxylase and DOPA decarboxylase can be delivered by the techniques described herein in order to treat such diseases as Parkinson's. In addition, the enzymes responsible for neurotransmitter synthesis can be delivered using the systems described herein. For example, the gene for choline acetyl transferase may be expressed within the brain cells (neurons or glial) of specific areas to increase acetylcholine levels and improve brain function. For treating multiple sclerosis, the genes encoding MPIF-1, MIP-4, M-CIF and anti-inflammatory proteins can be delivered (see, U.S. Patent No. 6,001,606).

These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings.

#### Detailed Description of the Invention

The practice of the present invention will employ, unless otherwise indicated, conventional methods of protein chemistry, biochemistry, recombinant DNA techniques and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., T.E. Creighton, *Proteins: Structures and Molecular Properties* (W.H. Freeman and Company, 1993); A.L. Lehninger, *Biochemistry* (Worth Publishers, Inc., current addition); Sambrook, et al., *Molecular Cloning: A Laboratory Manual* (2nd Edition, 1989); *Methods In Enzymology* (S. Colowick and N. Kaplan eds., Academic Press, Inc.); *Remington's Pharmaceutical Sciences*, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990).

It must be noted that, as used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "a gene" includes a mixture of two or more genes, and the like.

#### DEFINITIONS

In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.

"Gene delivery vehicle" refers to a construct which is capable of delivering, and, within preferred embodiments expressing, one or more gene(s) or sequence(s) of interest in a host cell. Representative examples of such vehicles include viral vectors, nucleic acid expression vectors, naked DNA, and certain eukaryotic cells (e.g., producer cells).

5 The terms "lentiviral vector construct," "lentiviral vector," and "recombinant lentiviral vector" are used interchangeably herein and refer to a nucleic acid construct derived from a lentivirus which carries, and within certain embodiments, is capable of directing the expression of a nucleic acid molecule of interest. Lentiviral vectors can have one or more of the lentiviral wild-type genes deleted in whole or part, as described  
10 further below, but retain functional flanking long-terminal repeat (LTR) sequences (also described below). Functional LTR sequences are necessary for the rescue, replication and packaging of the lentiviral virion. Thus, a lentiviral vector is defined herein to include at least those sequences required in *cis* for replication and packaging (e.g., functional LTRs) of the virus. The LTRs need not be the wild-type nucleotide sequences,  
15 and may be altered, e.g., by the insertion, deletion or substitution of nucleotides, so long as the sequences provide for functional rescue, replication and packaging.

Generally, a lentiviral vector includes at least one transcriptional promoter or promoter/enhancer or locus defining element(s), or other elements that control gene expression by other means such as alternate splicing, RNA export, post-translational  
20 modification of messenger, or post-transcriptional modification of protein. As explained above, such vector constructs also include a packaging signal, LTRs or functional portions thereof, and positive and negative strand primer binding sites appropriate to the retrovirus used (if these are not already present in the retroviral vector). Optionally, the recombinant lentiviral vector may also include a signal that directs polyadenylation,  
25 selectable and/or non-selectable markers, an origin of second strand DNA synthesis, as well as one or more restriction sites and a translation termination sequence. Examples of markers include, but are not limited to, neomycin (Neo), thymidine kinase (TK), hygromycin, phleomycin, puromycin, histidinol, green fluorescent protein (GFP), human placental alkaline phosphatase (PLAP), DHFR,  $\beta$ -galactosidase and human growth  
30 hormone (hGH). By way of example, such vectors typically include a 5' LTR, a tRNA

binding site, a packaging signal, an origin of second strand DNA synthesis, and a 3' LTR or a portion thereof.

The terms "FIV retroviral vector construct," "FIV vector," and "recombinant FIV vector" are used interchangeably to refer to a lentiviral vector construct, as defined above, which includes one or more FIV sequences. By way of example, such vectors typically include a 5' FIV LTR, a primer binding site, a packaging signal, an origin of second strand DNA synthesis, and a 3' FIV LTR. Heterologous sequences that are included in the vector construct are those which encode a protein, such as an enzyme, the expression of which is deficient in the selected target cells.

"Expression cassette" refers to an assembly which is capable of directing the expression of the sequence(s) or gene(s) of interest. The expression cassette includes a promoter or promoter/enhancer which is operably linked to (so as to direct transcription of) the sequence(s) or gene(s) of interest, and often includes a polyadenylation sequence as well. Within certain embodiments of the invention, the expression cassette described herein may be contained within a plasmid construct. In addition to the components of the expression cassette, the plasmid construct may also include a bacterial origin of replication, one or more selectable markers, a signal which allows the plasmid construct to exist as single-stranded DNA (e.g., a M13 origin of replication), at least one multiple cloning site, and a "mammalian" origin of replication (e.g., a SV40 or adenovirus origin of replication).

"Packaging cell" refers to a cell which contains those elements necessary for production of infectious recombinant retrovirus which are lacking in a recombinant retroviral vector. Packaging cells contain one or more expression cassettes which are capable of expressing proteins which encode *gag*, *pol* and *env*-derived proteins.

Packaging cells can also contain expression cassettes encoding one or more of *vif*, *rev*, or ORF 2 in addition to *gag/pol* and *env* expression cassettes.

"Producer cell" and "Vector Producing Cell Line" (VCL) refer to a cell which contains all elements necessary for production of recombinant vector particles.

"Lentiviral vector particle" as used herein refers to a recombinant lentivirus which carries at least one gene or nucleotide sequence of interest, which is generally flanked by

lentiviral LTRs. The lentivirus may also contain a selectable marker. The recombinant lentivirus is capable of reverse transcribing its genetic material into DNA and incorporating this genetic material into a host cell's DNA upon infection. Lentiviral vector particles may have a lentiviral envelope, a non-lentiviral envelope (e.g., an  
5 amphotropic or VSV-G envelope), a chimeric envelope or a modified envelope (e.g., truncated envelopes or envelopes containing hybrid sequences).

"FIV vector particle" as utilized herein refers to a lentiviral particle, as defined above, which is derived from FIV.

The term "transfection" is used to refer to the uptake of foreign DNA by a cell. A  
10 cell has been "transfected" when exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are generally known in the art. See, e.g., Graham et al. (1973) *Virology*, 52:456, Sambrook et al. (1989) *Molecular Cloning, a laboratory manual*, Cold Spring Harbor Laboratories, New York, Davis et al. (1986) *Basic Methods in Molecular Biology*, Elsevier, and Chu et al. *Gene* 13:197, 1981. Such  
15 techniques can be used to introduce one or more exogenous DNA moieties, such as a plasmid vector and other nucleic acid molecules, into suitable host cells. The term refers to both stable and transient uptake of the genetic material.

The term "transduction" denotes the delivery of a DNA molecule to a recipient cell either *in vivo* or *in vitro*, via a replication-defective viral vector, such as via a  
20 recombinant lentiviral vector particle.

The term "heterologous" as it relates to nucleic acid sequences such as gene sequences and control sequences, denotes sequences that are not normally joined together, and/or are not normally associated with a particular cell. Thus, a "heterologous" region of a nucleic acid construct or a vector is a segment of nucleic acid within or  
25 attached to another nucleic acid molecule that is not found in association with the other molecule in nature. For example, a heterologous region of a nucleic acid construct could include a coding sequence flanked by sequences not found in association with the coding sequence in nature. Another example of a heterologous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., synthetic sequences having  
30 codons different from the native gene). Similarly, a cell transformed with a construct

which is not normally present in the cell would be considered heterologous for purposes of this invention. Allelic variation or naturally occurring mutational events do not give rise to heterologous DNA, as used herein.

The term "control elements" refers collectively to promoter regions,  
5 polyadenylation signals, transcription termination sequences, upstream regulatory domains, origins of replication, internal ribosome entry sites ("IRES"), enhancers, and the like, which collectively provide for the replication, transcription and translation of a coding sequence in a recipient cell. Not all of these control elements need always be present so long as the selected coding sequence is capable of being replicated, transcribed  
10 and translated in an appropriate host cell.

The term "promoter region" is used herein in its ordinary sense to refer to a nucleotide region comprising a DNA regulatory sequence, wherein the regulatory sequence is derived from a gene which is capable of binding RNA polymerase and initiating transcription of a downstream (3'-direction) coding sequence.

15 "Operably linked" refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function. Thus, control elements operably linked to a coding sequence are capable of effecting the expression of the coding sequence. The control elements need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. Thus, for example, intervening  
20 untranslated yet transcribed sequences can be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence.

For the purpose of describing the relative position of nucleotide sequences in a particular nucleic acid molecule throughout the instant application, such as when a  
25 particular nucleotide sequence is described as being situated "upstream," "downstream," "5," or "3" relative to another sequence, it is to be understood that it is the position of the sequences in the non-transcribed strand of a DNA molecule that is being referred to as is conventional in the art.

By "isolated" when referring to a nucleotide sequence, is meant that the indicated  
30 molecule is present in the substantial absence of other biological macromolecules of the

same type. Thus, an "isolated nucleic acid molecule which encodes a particular polypeptide" refers to a nucleic acid molecule which is substantially free of other nucleic acid molecules that do not encode the subject polypeptide; however, the molecule may include some additional bases or moieties which do not deleteriously affect the basic characteristics of the composition.

"Homology" refers to the percent identity between two polynucleotide or two polypeptide moieties. Two DNA, or two polypeptide sequences are "substantially homologous" to each other when the sequences exhibit at least about 50% , preferably at least about 75%, more preferably at least about 80%-85%, preferably at least about 90%, and most preferably at least about 95%-98% sequence identity over a defined length of the molecules. As used herein, substantially homologous also refers to sequences showing complete identity to the specified DNA or polypeptide sequence.

In general, "identity" refers to an exact nucleotide-to-nucleotide or amino acid-to-amino acid correspondence of two polynucleotides or polypeptide sequences, respectively. Percent identity can be determined by a direct comparison of the sequence information between two molecules by aligning the sequences, counting the exact number of matches between the two aligned sequences, dividing by the length of the shorter sequence, and multiplying the result by 100. Readily available computer programs can be used to aid in the analysis, such as ALIGN, Dayhoff, M.O. in *Atlas of Protein Sequence and Structure* M.O. Dayhoff ed., 5 Suppl. 3:353-358, National biomedical Research Foundation, Washington, DC, which adapts the local homology algorithm of Smith and Waterman *Advances in Appl. Math.* 2:482-489, 1981 for peptide analysis. Programs for determining nucleotide sequence identity are available in the Wisconsin Sequence Analysis Package, Version 8 (available from Genetics Computer Group, Madison, WI) for example, the BESTFIT, FASTA and GAP programs, which also rely on the Smith and Waterman algorithm. These programs are readily utilized with the default parameters recommended by the manufacturer and described in the Wisconsin Sequence Analysis Package referred to above. For example, percent identity of a particular nucleotide sequence to a reference sequence can be determined using the

homology algorithm of Smith and Waterman with a default scoring table and a gap penalty of six nucleotide positions.

Another method of establishing percent identity in the context of the present invention is to use the MPSRCH package of programs copyrighted by the University of  
5 Edinburgh, developed by John F. Collins and Shane S. Sturrok, and distributed by IntelliGenetics, Inc. (Mountain View, CA). From this suite of packages the Smith-Waterman algorithm can be employed where default parameters are used for the scoring table (for example, gap open penalty of 12, gap extension penalty of one, and a gap of six). From the data generated the "Match" value reflects "sequence identity." Other  
10 suitable programs for calculating the percent identity or similarity between sequences are generally known in the art, for example, another alignment program is BLAST, used with default parameters. For example, BLASTN and BLASTP can be used using the following default parameters: genetic code = standard; filter = none; strand = both; cutoff = 60; expect = 10; Matrix = BLOSUM62; Descriptions = 50 sequences; sort by = HIGH  
15 SCORE; Databases = non-redundant, GenBank + EMBL + DDBJ + PDB + GenBank CDS translations + Swiss protein + Spupdate + PIR. Details of these programs can be found at the following internet address: <http://www.ncbi.nlm.gov/cgi-bin/BLAST>.

Alternatively, homology can be determined by hybridization of polynucleotides under conditions which form stable duplexes between homologous regions, followed by  
20 digestion with single-stranded-specific nuclease(s), and size determination of the digested fragments. DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Sambrook et al., *supra*; *DNA Cloning, supra*; *Nucleic Acid*  
25 *Hybridization, supra*.

By "vertebrate subject" is meant any member of the subphylum chordata, including, without limitation, mammals such as cattle, sheep, pigs, goats, horses, and human and non-human primates; domestic animals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs, and the like; birds,  
30 including domestic, wild and game birds such as cocks and hens including chickens,

turkeys and other gallinaceous birds; and fish. The term does not denote a particular age. Thus, both adult and newborn animals, as well as fetuses, are intended to be covered.

#### MODES OF CARRYING OUT THE INVENTION

5        Before describing the present invention in detail, it is to be understood that this invention is not limited to particular formulations or process parameters as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting.

10       Although a number of compositions and methods similar or equivalent to those described herein can be used in the practice of the present invention, the preferred materials and methods are described herein.

As noted above, the present invention provides methods for treating, preventing, or, inhibiting diseases of the CNS and brain, comprising the general step of administering  
15 a recombinant lentiviral vector which directs the expression of one or more polypeptides, proteins or enzymes, such that the disease is treated or prevented. The invention is also directed to transducing neural progenitor cells and cerebellar neurons, such as Purkinje cells. The invention is based on the surprising finding that FIV-based vectors can infect cerebellar neurons, as well as progenitor cell populations. Moreover, infection does not  
20 inhibit the ability of neural progenitor cells to differentiate into multiple cell types, or to respond to injury within the CNS. Thus, the present invention provides for the use of genetically-manipulated stem cells for CNS therapies.

In order to further an understanding of the invention, a more detailed discussion is provided below regarding (A) gene delivery vectors; (B) polypeptides, proteins or  
25 enzymes for use in treating cerebellar diseases; and (C) methods of administering the gene delivery vectors in the treatment or prevention of these diseases.



A. Gene Delivery Vectors

1. Construction of retroviral gene delivery vectors

Within one aspect of the present invention, retroviral gene delivery vehicles are provided which are constructed to carry or express a selected gene(s) or sequence(s) of interest. Briefly, retroviral gene delivery vehicles of the present invention may be readily constructed from a wide variety of retroviruses, including for example, B, C, and D type retroviruses as well as spumaviruses and lentiviruses such as FIV, HIV, HIV-1, HIV-2 and SIV (see RNA Tumor Viruses, Second Edition, Cold Spring Harbor Laboratory, 1985). Such retroviruses may be readily obtained from depositories or collections such as the American Type Culture Collection ("ATCC"; 10801 University Blvd., Manassas, VA 20110-2209), or isolated from known sources using commonly available techniques.

Any of the above retroviruses may be readily utilized in order to assemble or construct retroviral gene delivery vehicles given the disclosure provided herein, and standard recombinant techniques (e.g., Sambrook et al, *Molecular Cloning: A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory Press, 1989; Kunkle, *PNAS* 82:488, 1985). In addition, within certain embodiments of the invention, portions of the retroviral gene delivery vehicles may be derived from different retroviruses. For example, within one embodiment of the invention, retrovector LTRs may be derived from a Murine Sarcoma Virus, a tRNA binding site from a Rous Sarcoma Virus, a packaging signal from a Murine Leukemia Virus, and an origin of second strand synthesis from an Avian Leukosis Virus.

Within one aspect of the present invention, retrovector constructs are provided comprising a 5' LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand DNA synthesis and a 3' LTR, wherein the vector construct lacks *gag/pol* or *env* coding sequences.

Within certain embodiments of the invention, retrovirus vectors are provided wherein viral promoters, preferably CMV or SV40 promoters and/or enhancers are utilized to drive expression of one or more genes of interest.

Within other aspects of the invention, retrovirus vectors are provided wherein tissue-specific promoters are utilized to drive expression of one or more genes of interest.

Retrovirus vector constructs for use with the subject invention may be generated such that more than one gene of interest is expressed and preferably secreted. This may  
5 be accomplished through the use of di- or oligo-cistronic cassettes (e.g., where the coding regions are separated by 120 nucleotides or less, see generally Levin et al., *Gene* 108:167-174, 1991), or through the use of Internal Ribosome Entry Sites ("IRES").

Within one aspect of the invention, self-inactivating (SIN) vectors are made by deleting promoter and enhancer elements in the U3 region of the 3'LTR, including the  
10 TATA box and binding sites for one or more transcription factors. The deletion is transferred to the 5'LTR after reverse transcription and integration in transduced cells. This results in the transcriptional inactivation of the LTR in the provirus. Possible advantages of SIN vectors include increased safety of the gene delivery system as well as the potential to reduce promoter interference between the LTR and the internal promoter  
15 which may result in increased expression of the gene of interest. Furthermore, it is reasonable to expect tighter control of regulatable gene therapy vectors due to the lack of an upstream promoter element in the 5'LTR.

FIV vectors are particularly preferred for use herein. FIV vectors may be readily constructed from a wide variety of FIV strains. Representative examples of FIV strains  
20 and molecular clones of such isolates include the Petaluma strain and its molecular clones FIV34TF10 and FIV14 (Olmsted et al., *PNAS* 86:8088-8092, 1989; Olmsted et al., *PNAS* 86:2448-2452, 1989; Talbot et al., *PNAS* 86:5743-5747, 1989), the San Diego strain and its molecular clone PPR (Phillips et al., *J. Virology* 64:4605-4613, 1990), the Japanese strains and their molecular clones FTM191CG and FIV-TM2 (Miyazawa et al., *J.*  
25 *Virology* 65:1572-1577, 1991) and the Amsterdam strain and its molecular clone 19K1 (Siebelink et al., *J. Virology* 66:1091-1097, 1992). Such FIV strains may either be obtained from feline isolates, or more preferably, from depositories or collections such as the ATCC, or isolated from known sources using commonly available techniques.

Any of the above FIV strains may be readily utilized in order to assemble or  
30 construct FIV gene delivery vehicles given the disclosure provided herein, and standard

recombinant techniques (e.g., *Sambrook et al., Molecular Cloning: A laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, 1989; Kunkle, *PNAS* 82:488, 1985; International Publication Nos. WO 99/15641 and WO 99/36511). In addition, within certain embodiments of the invention, portions of the FIV gene delivery vehicles may be derived from different viruses. For example, within one embodiment of the invention, recombinant FIV vector or LTR sequences may be partially derived or obtained from HIV, a packaging signal from SIV, and an origin of second strand synthesis from HIV-2.

Within one aspect of the present invention, FIV vector constructs are provided comprising a 5' FIV LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand DNA synthesis, an RNA export element and a 3' FIV LTR. Briefly, Long Terminal Repeats ("LTRs") are subdivided into three elements, designated U5, R and U3. These elements contain a variety of signals which are responsible for the biological activity of a retrovirus, including for example, promoter and enhancer elements which are located within U3. LTRs may be readily identified in the provirus (integrated DNA form) due to their precise duplication at either end of the genome. For purposes of the present invention, a 5' FIV LTR should be understood to include as much of the native 5' FIV LTR in order to function as a 5' promoter or promoter/enhancer element to allow reverse transcription and integration of the DNA form of the vector. The 3' FIV LTR should be understood to include as much of the 3' FIV LTR to function as a polyadenylation signal to allow reverse transcription and integration of the DNA form of the vector.

Additionally, FIV vector constructs may contain hybrid FIV LTRs where up to 75% of the wildtype FIV LTR sequence is deleted and replaced by one or more viral or non-viral promoter or promoter/enhancer elements (e.g., other retroviral LTRs and/or non-retroviral promoters or promoter/enhancers such as the CMV promoter/enhancer or the SV40 promoter) similar to the hybrid LTRs described by Chang, et al., *J. Virology* 67, 743-752, 1993; Finer, et al., *Blood* 83, 43-50, 1994 and Robinson, et al., *Gene Therapy* 2, 269-278, 1995.

The tRNA binding site and origin of second strand DNA synthesis are also important for a retrovirus to be biologically active, and may be readily identified by one

of skill in the art. For example, tRNA binds to a retroviral tRNA binding site by Watson-Crick base pairing, and is carried with the retrovirus genome into a viral particle. The tRNA is then utilized as a primer for DNA synthesis by reverse transcriptase. The tRNA binding site may be readily identified based upon its location just downstream from the 5' LTR. Similarly, the origin of second strand DNA synthesis is, as its name implies, important for the second strand DNA synthesis of a retrovirus. This region, which is also referred to as the poly-purine tract, is located just upstream of the 3' LTR.

The packaging signal sequence of FIV directs packaging of viral genetic material into the viral particle. A major part of the packaging signal in FIV lies between the 5' FIV LTR and the *gag/pol* sequence with the packaging signal likely overlapping in part with the 5' area of the *gag/pol* sequence.

In addition to 5' and 3' FIV LTRs, a tRNA binding site, a packaging signal, and an origin of second strand DNA synthesis, certain preferred recombinant FIV vector constructs for use herein also comprise one or more genes of interest, each of which is discussed in more detail below. In addition, the FIV vectors may, but need not, include an RNA export element (also variously referred to as RNA transport, nuclear transport or nuclear export elements) which may be the FIV RRE (Rev-responsive element) or a heterologous transport element. Representative examples of suitable heterologous RNA export elements include the Mason-Pfizer monkey virus constitutive transport element, the MPMV CTE (Bray et al., *PNAS USA* 91, 1256-1260, 1994), the Hepatitis B Virus posttranscriptional regulatory element, the HBV PRE (Huang et al., *Mol. Cell. Biol.* 13:7476-7486, 1993 and Huang et al., *J. Virology* 68:3193-3199, 1994), other lentiviral Rev-responsive elements (Daly et al., *Nature* 342:816-819, 1989 and Zapp et al., *Nature* 342:714-716, 1989) or the PRE element from the woodchuck hepatitis virus. Further RNA export elements include the element in Rous sarcoma virus (Ogert et al., *J. Virology* 70:3834-3843, 1996; Liu & Mertz, *Genes & Dev.* 9:1766-1789, 1995) and the element in the genome of simian retrovirus type 1 (Zolotukhin et al., *J. Virology* 68:7944-7952, 1994). Other potential elements include the elements in the histone gene (Kedes, *Annu. Rev. Biochem.* 48:837-870, 1970), the  $\alpha$  interferon gene (Nagata et al., *Nature* 287:401-

408, 1980), the  $\beta$ -adrenergic receptor gene (Koilkka et al., *Nature* 329:75-79, 1987), and the c-Jun gene (Hattorie et al., *PNAS* 85:9148-9152, 1988).

FIV vector constructs which lack both *gag/pol* and *env* coding sequences may be used with the present invention. As utilized herein, the phrase "lacks *gag/pol* or *env* coding sequences" should be understood to mean that the FIV vector contains less than 20, preferably less than 15, more preferably less than 10, and most preferably less than 8 consecutive nucleotides which are found in *gag/pol* or *env* genes, and in particular, within *gag/pol* or *env* expression cassettes that are used to construct packaging cell lines for the FIV vector construct. This aspect of the invention provides for FIV vectors having a low probability of undesirable recombination with *gag/pol* or *env* sequences which may occur in a host cell or be introduced therein, for example, by transformation with an expression cassette. The production of FIV vector constructs lacking *gag/pol* or *env* sequences may be accomplished by partially eliminating the packaging signal and/or the use of a modified or heterologous packaging signal. Within other embodiments of the invention, FIV vector constructs are provided wherein a portion of the packaging signal that may extend into, or overlap with, the FIV *gag/pol* sequence is modified (e.g., deleted, truncated or bases exchanged). Within other aspects of the invention, FIV vector constructs are provided which include the packaging signal that may extend beyond the start of the *gag/pol* gene. Within certain embodiments, the packaging signal that may extend beyond the start of the *gag/pol* gene is modified in order to contain one, two or more stop codons within the *gag/pol* reading frame. Most preferably, one of the stop codons eliminates the *gag/pol* start site. In other embodiments, the introduced mutation may cause a frame shift in the *gag/pol* coding region.

Other retroviral gene delivery vehicles may likewise be utilized within the context of the present invention, including for example those described in EP 0,415,731; WO 90/07936; WO 91/0285, WO 9403622; WO 9325698; WO 9325234; U.S. Patent No. 5,219,740; WO 9311230; WO 9310218; Vile and Hart, *Cancer Res.* 53:3860-3864, 1993; Vile and Hart, *Cancer Res.* 53:962-967, 1993; Ram et al., *Cancer Res.* 53:83-88, 1993; Takamiya et al., *J. Neurosci. Res.* 33:493-503, 1992; Baba et al., *J. Neurosurg.* 79:729-735, 1993 (U.S. Patent No. 4,777,127, GB 2,200,651, EP 0,345,242 and WO91/02805).

Packaging cell lines suitable for use with the above described retrovector constructs may be readily prepared (see, e.g., U.S. Patent Nos. 5,591,624 and 6,013,517; and International Publication No. WO 95/30763), and utilized to create producer cell lines (also termed vector cell lines or "VCLs") for the production of recombinant vector particles. Briefly, the parent cell line from which the packaging cell line is derived can be selected from a wide variety of mammalian cell lines, including for example, human cells, monkey cells, feline cells, dog cells, mouse cells, and the like.

For example, potential packaging cell line candidates are screened by isolating the human placental alkaline phosphatase (PLAP) gene from the N2-derived retroviral vector pBAAP, and inserting the gene into the FIV vector construct. To generate infectious virus, the construct is co-transfected with a VSV-G encoding expression cassette (e.g., pMLP-G as described by Emi et al., *J. Virology* 65, 1202-1207, 1991; or pCMV-G, see US Patent No. 5,670,354) into 293T cells, and the virus harvested 48 hours after transfection. The resulting virus can be utilized to infect candidate host cells which are subsequently FACS-analyzed using antibodies specific for PLAP. Candidate host cells include, e.g., human cells such as HeLa (ATCC CCL 2.1), HT-1080 (ATCC CCL 121), 293 (ATCC CRL 1573), Jurkat (ATCC TIB 153), supT1 (NIH AIDS Research and Reference reagent program catalog #100), and CEM (ATCC CCL 119) or feline cells such as CrFK (ATCC CCL 94), G355-5 (Ellen et al., *Virology* 187:165-177, 1992), MYA-1 (Dahl et al., *J. Virology* 61:1602-1608, 1987) or 3201-B (Ellen et al., *Virology* 187:165-177, 1992). Production of p24 and reverse transcriptase can also be analyzed in the assessment of suitable packaging cell lines.

After selection of a suitable host cell for the generation of a packaging cell line, one or more expression cassettes are introduced into the cell line in order to complement or supply in *trans* components of the vector which have been deleted (see, e.g., U.S. Patent Nos. 5,591,624 and 6,013,517, incorporated herein by reference in their entireties; and International Publication No. WO 95/30763). For example, packaging expression cassettes may encode either *gag/pol* sequences alone, *gag/pol* sequences and one or more of *vif*, *rev* or ORF 2, or one or more of *vif*, *rev* or ORF 2 alone and may contain an RNA

export element. For example, the packaging cell line may contain only ORF 2, *vif*, or *rev* alone, ORF 2 and *vif*, ORF 2 and *rev*, *vif* and *rev* or all three of ORF 2, *vif* and *rev*.

Packaging cell lines may also comprise a promoter and a sequence encoding ORF 2, *vif*, *rev*, or an envelope (e.g., VSV-G), wherein the promoter is operably linked to the sequence encoding ORF 2, *vif*, *rev*, or the envelope. For packaging cell lines containing inducible *gag/pol* or *env* expression cassettes, additional expression cassettes facilitating the transactivation of the inducible promoter may be incorporated.

The expression cassette may or may not be stably integrated. The packaging cell line, upon introduction of an FIV vector, may produce particles at a concentration of greater than  $10^3$ ,  $10^4$ ,  $10^5$ ,  $10^6$ ,  $10^7$ ,  $10^8$ , or,  $10^9$  cfu/ml.

Preferably, lentiviral vector particles are constructed to provide for replacement of both the defective gene product and cells. For gene product replacement using neural progenitors, it is preferable that the product is secreted and is able to rescue surrounding cells. For cell replacement, progenitors should generally maintain migratory potential and integrate appropriately into degenerating regions. The use of FIV-based vectors for infection of neural progenitor cells, without significant effect on self-renewal, allows stable expression of therapeutic transgenes in progenitor cells. Lentiviral vector particles may also be used to introduce genes for enhanced cell type-specific differentiation or migration in the degenerating brain.

#### B. Treatment of CNS and Brain Diseases

In humans, there are numerous inherited metabolic diseases affecting the CNS, many of which result in cerebellar degeneration with concomitant symptoms such as dysmetria, ataxia, past pointing, dysdiadochokinesia, dysarthria, intention and action tremor, cerebellar nystagmus, rebound, hypotonia, and loss of equilibrium. These diseases may be alleviated using lentiviral-based, and in particular, FIV-based gene therapy as disclosed herein.

Diseases of the CNS and brain in humans that are amenable to treatment using the methods of the invention include a wide variety of diseases and disorders, including for

example, spinocerebellar ataxias (SCA) such as SCA-1, SCA-2, SCA-3, SCA-6, and SCA-7; cerebellar degeneration due to alcoholism; idiopathic Purkinje cell degeneration; lithium intoxication; ceroid lipofuscinosis; ataxia telangiectasia; high dose arabinoside; Huntington's disease; fragile X syndrome; hereditary motor and sensory neuropathy and cerebellar atrophy; Alzheimer's disease (both sporadic and familial); normal aging; Parkinson's Disease and Parkinson's disease-like symptoms such as muscle tremors, muscle weakness, rigidity, bradykinesia, alterations in posture and equilibrium and dementia; demyelinating diseases such as, but not limited to, multiple sclerosis, parainfectious disorders such as acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalopathy, viral infections such as progressive multifocal leukoencephalopathy and subacute sclerosing panencephalitis, nutritional disorders such as vitamin B<sub>12</sub> deficiency, demyelination of the corpus callosum (Marchiafava-Bignami disease) and central pontine myelinolysis, anoxic-ischemic sequelae such as delayed postanoxic cerebral demyelination and progressive subcortical ischemic encephalopathy; demyelinating diseases such as, but not limited to, the leukocystrophies such as metachromatic leukodystrophy, sudanophilic (Pelizaeus-Merzbacher disease), globoid cell (Krabbe's disease), adrenoleukodystrophy (Schilder's disease), Alexander's disease, Canavan's disease, Seitelberger's disease, aminoacidurias; multisystem atrophy; paraneoplastic Purkinje cell degeneration; metachromatic leukodystrophy (enzyme-deficient and activator-deficient form); manic depression; bipolar disorders; schizophrenia; autism; and the like.

Accordingly, the methods of the present invention may be used to alleviate abnormalities of the CNS and cerebellum that result in demyelination, dysmyelination, dementia, dysmetria, ataxia, past pointing, dysdiadochokinesia, dysarthria, intention and action tremor, cerebellar nystagmus, rebound, hypotonia, and loss of equilibrium.

Genes encoding a wide variety of polypeptides, proteins or enzymes may be employed, including those which, when expressed, prevent or alleviate the effects of the particular CNS and/or cerebellar disorder in question. Examples of such proteins include, but are not limited to CLN2 (tripeptidyl protease; ttp); CLN3; CLN1 (protein palmitoyl thioesterase); calbindin; glutamate decarboxylase; the genes encoding proteins



deficient in SCA-1, SCA-2, SCA-3, SCA-6, and SCA-7; ataxin (1-7); arylsulfatase A, sulfatide activator/saposin; galactosylceramidase; various growth factors such as any of the various NGFs and FGFs, as well as CNTF, BDNF, GDNF, NT3, NT4/5, and IGF-1; monoamine oxidase; tyrosine hydroxylase; the Huntington (htt) gene; bipolar genes such as G-protein alpha subunit gene and Galphaz (GNAZ); serotonin transporter gene; serotonin receptor HTR-7, genes in the VCSF region of chromosome 22; and anti-apoptotic genes. Moreover, critical enzymes involved in the synthesis of neurotransmitters such as dopamine, norepinephrine, and GABA have been cloned and available and can be used to treat a broad range of brain disease in which disturbed neurotransmitter function plays a crucial role, such as schizophrenia, manic-depressive illnesses and Parkinson's Disease. It is well established that patients with Parkinson's suffer from progressively disabled motor control due to the lack of dopamine synthesis within the basal ganglia. The rate limiting step for dopamine synthesis is the conversion of tyrosine to L-DOPA by the enzyme, tyrosine hydroxylase. L-DOPA is then converted to dopamine by the ubiquitous enzyme, DOPA decarboxylase. Thus, the genes for tyrosine hydroxylase and DOPA decarboxylase can be delivered by the techniques described herein in order to treat such diseases as Parkinson's. In addition, the enzymes responsible for neurotransmitter synthesis can be delivered using the systems described herein. For example, the gene for choline acetyl transferase may be expressed within the brain cells (neurons or glial) of specific areas to increase acetylcholine levels and improve brain function. For treating multiple sclerosis, the genes encoding MIPF-1, MIP-4 and M-CIF can be delivered (see, U.S. Patent No. 6,001,606).

The methods of the invention also have use in the veterinary field including treatment of domestic pets and farm animals.

As utilized herein, the terms "treated, prevented, or, inhibited" refer to the alteration of a disease course or progress in a statistically significant manner. Determination of whether a disease course has been altered may be readily assessed in a variety of model systems and by using standard assays, known in the art, which analyze the ability of a gene delivery vector to delay or prevent CNS or cerebellar degeneration.

### 1. Methods of Administration

Gene delivery vectors may be delivered directly to the CNS or brain by injection into, e.g., a ventricle, a cerebellar lobule and/or the striatum, using a needle, catheter or related device. In particular, within certain embodiments of the invention, one or more dosages may be administered directly in the indicated manner at dosages greater than or equal to  $10^3$ ,  $10^4$ ,  $10^5$ ,  $10^6$ ,  $10^7$ ,  $10^8$ ,  $10^9$ ,  $10^{10}$  or  $10^{11}$  cfu. Cerebellar injections are complicated by the fact that stereotaxic coordinates cannot be used to precisely target the site of an injection; there is animal to animal variation in the size of cerebellar lobules, as well as their absolute three-dimensional orientation. Thus, cholera toxin subunit b (CTb) may be used to determine the exact location of the injection and reveal the pool of transducible neurons at an injection site. Injections may fill the molecular layer, Purkinje cell layer, granule cell layer and white matter of the arbor vitae but do not extend to the deep cerebellar nuclei.

Alternatively, and preferably for treating diseases using transduced neural progenitor cells, neural progenitor cells are first transduced *ex vivo* and then delivered to the CNS. Generally, if transduced *ex vivo*, cells will be infected with the viral vectors described herein at an MOI of about 0.01 to about 50, preferably about 0.05 to about 30, and most preferably about 0.1 to about 20 MOI. For FIV vectors, an MOI of about 0.05 to about 10, preferably about 0.1 to about 5, or even 0.1 to about 1, should be sufficient.

Once transfected *ex vivo*, cells can be delivered, for example, to the ventricular region, as well as to the striatum, spinal cord and neuromuscular junction, using neurosurgical techniques known in the art, and as described in the examples below, such as by stereotactic injection and injections into the eyes and ears (see, e.g., Stein et al., *J Virol* 73:3424-3429, 1999; Davidson et al., *PNAS* 97:3428-3432, 2000; Davidson et al., *Nat. Genet.* 3:219-223, 1993; and Alisky and Davidson, *Hum. Gene Ther.* 11:2315-2329, 2000). In general, the amount of transduced cells in the compositions to be delivered to the subject will be from about  $10^1$  to about  $10^{10}$  cells or more, more preferably about  $10^1$  to  $10^8$  cells or more, and even more preferably about  $10^2$  to about  $10^4$  cells, or more. Other effective dosages can be readily established by one of ordinary skill in the art through routine trials establishing dose response curves.

## 2. Assays

A wide variety of assays may be utilized in order to determine appropriate dosages for administration, or to assess the ability of a gene delivery vector to treat or prevent a particular disease. Certain of these assays are discussed in more detail below.

For example, the ability of particular vectors to transduce cerebellar neurons and neural progenitor cells can be assessed using reporter genes, as discussed below. The ability of the transduced progenitor cells to differentiate may be tested, for example, using immunocytochemistry, as discussed below in the examples.

## 3. Neurological function

In mice, neurological function can be measured by EEG. Behavioral, memory, and cognitive function can be assayed using techniques known in the art. See, e.g., Chang et al., *Neuro Report* 4:507-510, 1993.

## 4. Neural tissue analysis

Tissues can be harvested from treated mice or primates, and processed for evaluation of neuronal degeneration, regeneration and differentiation using routine procedures. In this invention it is useful to evaluate, for example, various cerebellar neuronal tissues, including cells in the molecular layer such as Purkinje cells, stellate and basket neurons, as well as cells in the granule layer, such as fusiform Golgi neurons and granule cell neurons. Measurements performed over time can indicate increasing correction of cells distant to the vector administration site. CSF can also be collected and evaluated for protein levels or enzyme activity, particularly if the vector encodes a secretable enzyme.

## 5. Pharmaceutical Compositions

Gene delivery vectors may be prepared as a pharmaceutical product suitable for direct administration. Within preferred embodiments, the vector should be admixed with a pharmaceutically acceptable excipients or vehicles, and optionally other therapeutic

and/or prophylactic ingredients. Such excipients include liquids such as water, saline, phosphate buffered saline, glycerol, polyethyleneglycol, hyaluronic acid, ethanol, etc. Pharmaceutically acceptable salts can be used in the compositions of the present invention and include, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients and salts is available in *Remington's Pharmaceutical Sciences*, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990).

Additionally, auxiliary substances, such as wetting or emulsifying agents, biological buffering substances, surfactants, and the like, may be present in such vehicles. A biological buffer can be virtually any solution which is pharmacologically acceptable and which provides the formulation with the desired pH, i.e., a pH in the physiologically acceptable range. Examples of buffer solutions include saline, phosphate buffered saline, Tris buffered saline, Hank's buffered saline, and the like.

The delivery vectors may be provided in kits with suitable instructions and other necessary reagents, in order to transduce cells as described above. The kits can also contain, depending on the particular delivery vector used, suitable packaged reagents and materials (i.e. pharmaceutical excipients, catheters and the like).

#### EXPERIMENTAL

Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

Restriction and modifying enzymes, as well as other reagents for DNA manipulations were purchased from commercial sources, and used according to the manufacturers' directions. In the cloning of DNA fragments, except where noted, all

DNA manipulations were done according to standard procedures. See, e.g., Sambrook et al., *supra*.

#### EXAMPLE 1

##### 5 PRODUCTION OF RECOMBINANT FIV VECTOR PARTICLES FOR USE IN TRANSDUCING CEREBELLAR CELLS

FIV vectors expressing *E. coli*  $\beta$ -galactosidase were generated which were devoid of *vif* and ORF 2 (FIV $\beta$ gluc $\Delta$ vif $\Delta$ orf2), were generated essentially as described in International Publication No. WO 99/36511, published July 22, 1999. Specifically, FIV  
10 packaging constructs were generated in a series of steps from the full-length FIV molecular clone, FIV-34TF10 (NIH AIDS Research and Reference Reagent Program, Cat. No. 1236; Phillips et al., *J. Virol.* 66: 5464, 1992, Talbott et al., *PNAS* 86: 5743, 1989) as described (Johnston et al., *J Virol* 73:4991-5000, 1999). The FIV vector construct, pVET<sub>L</sub>C $\beta$ gal (pVET<sub>L</sub>C $\beta$  in ref (Johnston et al., *J Virol* 73:4991-5000, 1999),  
15 was generated by inserting an expression cassette consisting of the CMV promoter followed by the  $\beta$ -galactosidase gene into the pVET<sub>L</sub> FIV vector backbone. The pVET<sub>L</sub> backbone contains the FIV 5' LTR, in which the FIV U3 region is replaced by the CMV promoter/enhancer, 0.5 kb of Gag coding region, a multicloning site and the FIV 3' LTR (Johnston et al., *J Virol* 73:4991-5000, 1999). All constructs were screened by restriction  
20 enzyme digestion and the sequence of regions amplified by PCR confirmed by sequence analysis. Oligonucleotides were synthesized by Operon Technologies, Inc.(Alameda, CA) and sequences as well as more detailed cloning methods are available upon request.

Construction of the VSV-G envelope expression plasmid, pCMV-G, has been described (Yee et al., *PNAS* 91:9564-9568, 1994). Pseudotyped FIV $\beta$ gal vector particles  
25 were generated by transient transfection of plasmid DNA into 293T cells plated one day prior to transfection at a density of  $2.8 \times 10^6$  cells per 10 cm diameter culture dish. Cotransfections were performed using a 1:2:1 molar ratio of FIV packaging construct, FIV vector construct and VSV-G envelope-expressing plasmid. DNA complexes were prepared using calcium phosphate (Profectin kit; Promega Corp. Madison, WI) and  
30 transfected into cells according to the manufacturer's instructions. The medium was

replaced 8-16 hr after transfection and the supernatant harvested twice between 32 and 48 hr after the start of transfection. The harvested supernatants were filtered through a 0.45 M Nalgene filter and stored at -70 °C or concentrated prior to storage. Supernatants were concentrated by centrifugation (Johnston et al., *J Virol* 73:4991-5000). Vector titers were determined on HT1080 cells by serial dilution and assay for  $\beta$ -galactosidase (Li et al., *PNAS* 92:7700-7704, 1995). rFIV titers were approximately  $5-10 \times 10^7$  infectious units/ml.

In some experiments, a neuronal tracer, cholera toxin subunit b (CTb, List Laboratories, California), was added at 1  $\mu\text{g}/\mu\text{l}$  to the viral suspension. CTb is the nontoxic subunit of cholera toxin and has previously been used to define the limits of an injection site in experiments with pseudorabies virus (Chen et al., *Brain Research* 838:171-183, 1999). In this study, CTb immunoreactivity allowed independent visualization of cerebellar injection sites. In this manner, transport and spread of virus outside of the injection site could be distinguished from transduction within the primary injection site.

## EXAMPLE 2

### USE OF RECOMBINANT FIV VECTOR PARTICLES

#### TO TRANSDUCE CEREBELLAR CELLS

Young adult C57BL/6 mice weighing 20-25 g were anesthetized with ketamine/xylazine. A burr hole was drilled at the midline posterior occipital bone overlying the cerebellar anterior lobe. Pressure injections (2  $\mu\text{l}$  total) were made into a single cerebellar lobule using a Hamilton syringe cemented with a glass micropipette tip. A total of 16 animals were injected with rFIV $\beta$ gal; 8 with rFIV $\beta$ gal alone and 8 with rFIV $\beta$ gal plus CTb. Animals were sacrificed at 3, 6 (rFIV $\beta$ gal) or 7 (rAAV $\beta$ gal) weeks after gene transfer and cerebella, brainstems and thoracolumbar spinal cords removed. Tissues were postfixed in 4% paraformaldehyde overnight at 4 °C, cryoprotected for 1-3 days in 30% sucrose in phosphate buffered saline at 4 °C and then sectioned on a cryostat

at 50  $\mu\text{m}$  thickness (cerebellum/brainstem sagittally and spinal cord longitudinally). All sections were collected and stored at  $-20\text{ }^{\circ}\text{C}$  until use.

For histochemistry and immunofluorescence, every other section was processed for  $\beta$ -galactosidase activity using 5-bromo-4-chloro-4-indolyl  $\beta$ -D-galactoside (X-Gal) according to Davidson et al. (Davidson et al., *PNAS* 97:3428-3432, 2000). Transport and spread of virus was determined by comparing the X-gal processed sections to adjacent sections that had been processed for CTb immunohistochemistry. CTb immunohistochemistry was done according to Alisky and Tolbert, *J Neurosci* 52:143-148, 1994. Briefly, sections were blocked overnight in 2% rabbit serum in Tris-buffered saline, followed by 24 hours in goat anti-cholera toxin (List Laboratories) diluted 1/10,000. Sections were then incubated with biotinylated, rabbit anti-goat secondary antibodies and processed using an avidin-biotin peroxidase substrate. Neuronal versus glial transduction was determined by dual immunofluorescence for  $\beta$ -galactosidase and neuronal (calbindin) or glial (glial fibrillary acidic protein [GFAP]) markers on free-floating sections. Both anti-calbindin and anti-GFAP were purchased from Sigma Biochemicals (St. Louis, MO) and were used at a concentration of 1/3,000 or 1/1000, respectively. Immunofluorescence was evaluated using a confocal microscope and associated software.

$\beta$ -galactosidase-expressing Purkinje cells were counted in every other 50  $\mu\text{m}$  cerebellum section under a 10 x brightfield objective. Purkinje cells were selected for quantitation because they can be quickly counted in thicker sections without stereological correction.

Cerebellar injections are complicated by the fact that stereotaxic coordinates cannot be used to precisely target the site of an injection; there is animal to animal variation in the size of cerebellar lobules, as well as their absolute three-dimensional orientation. Cholera toxin subunit b (CTb) was therefore used. CTb is a reagent commonly used to track neurons from their termini or projections to their somata. The use of CTb allowed two advantages: First, the exact location of the injection could be determined. Second, it revealed the pool of potentially transducible neurons at an injection site. In mice injected with virus plus CTb, CTb-immunoreactivity was found

encompassing the targeted cerebellar lobule. In some cases, injections encompassed the dorsal half of one lobule and the ventral half of another lobule, while in other cases only a portion of a lobule was injected. At most, injections filled the molecular layer, Purkinje cell layer, granule cell layer and white matter of the arbor vitae but never extended to the deep cerebellar nuclei. Outside the injection site, the CTb retrogradely labeled precerebellar neurons in the cuneate, vestibular, olivary, reticular and spinal nuclei. Thus CTb co-injections mapped an extensive pool of neurons which could be potentially transduced via retrograde axonal transport of recombinant virus.

Histochemistry for  $\beta$ -galactosidase indicated that rFIV $\beta$ gal mediated transduction to large numbers of neurons. The cytoplasmically targeted  $\beta$ -galactosidase allowed detection of the Purkinje cell dendritic arbors, and also somata and their axonal extensions to the deep cerebellar and vestibular nuclei. The number of Purkinje cells transduced ranged from 78 to 1575 or 230 to 1298 in the rFIV $\beta$ gal or rFIV $\beta$ gal plus CTb-injected mice, respectively. Thus, CTb had no significant effect on rFIV-mediated gene transfer, either positively or negatively. The number of transduced Purkinje cells was proportional to the area positively labeled with CTb. For example, in cerebella with fewer CTb-labeled cells, there were fewer  $\beta$ -galactosidase-positive cells. Also, transduction was generally confined to the CTb-positive region. However, in some cerebella Purkinje cells in lobules adjacent to the injection site were also transduced.

In addition to Purkinje cells rFIV $\beta$ gal transduced stellate and basket neurons in the molecular layer. In the granule cell layer, large numbers of fusiform Golgi neurons were transduced, but only scattered granule cell neurons. Retrograde transport of rFIV $\beta$ gal was limited to deep cerebellar nuclei and lateral vestibular nuclei, which are the nuclei physically closest to the injection sites. Neurons in the cuneate, reticular, olivary and lumbar spinal nuclei were positive for CTb in rFIV $\beta$ gal, CTb co-injected animals. However, these neurons were never  $\beta$ -galactosidase positive, indicating that rFIV has a limited ability to be retrogradely transported. In all cases, FIV $\beta$ gal transduction was exclusively neuronal, with no co-localization of  $\beta$ -galactosidase with the glial marker GFAP.



To the best of the inventors' knowledge, this is the first report of direct gene transfer to cerebellar Purkinje cells. The above findings in the cerebellum are consistent with earlier results demonstrating transduction of cerebral neurons with recombinant lentivirus or AAV vectors. In addition the above data revealed selectivity among potential-target neurons, a previously unknown characteristic of rFIV vectors. This observation was likely made as a consequence of the morphologically distinct classes of neurons in each layer of the cerebellar cortex. Selective tropism could be more difficult to detect upon gene transfer to the basal ganglia, because lamination and neuronal subtypes are more complex.

Within the molecular layer of a cerebellar lobule, stellate cells are located towards the outside while basket neurons are nearer the Purkinje cell bodies. The gigantic Purkinje cells form a monolayer, while fusiform Golgi neurons and small granule neurons are exclusively in the granule cell layer. The above data show that rFIV-based vectors transduce neurons in the molecular and Purkinje cell layer, with limited transduction of Golgi neurons and almost no gene transfer to granule neurons. These data suggest that rFIV vectors are useful as therapies for diseases in which Purkinje cells degenerate.

The anterior lobe of the cerebellum receives input from multiple nuclei as well as the cervical and lumbar spinal cord segments. As such, injections into the cerebellum allowed for direct evaluation of the ability of rFIV-based vectors to undergo retrograde transport. Axonal transport with rFIV-based vectors was limited to the spatially closest nuclei.

Further studies with thin sections (10-20  $\mu$ ) and stereological sampling are done in order to quantify transduction of smaller neurons such as Golgi, stellate and basket cells and also to detect the small numbers of granule cells that are transduced. In the above study, X-gal reaction product filled the Purkinje cell dendrites of the molecular layer, making visualization of stellate and basket cells difficult. A two microliter injection ( $10^4$ - $10^5$  infectious units) into a single lobule transduced up to 1500 Purkinje cells. With an estimated 20,000 Purkinje cells in all 10 lobules of the mouse cerebellum (Caddy and Biscoe, *Brain Research* 111:306-398, 1976) approximately 10% of all Purkinje cells and close to 100% of the injected lobule were transduced. With injections into multiple

lobules it is reasonable to assume that most or all Purkinje cells could ultimately be transduced with rFIV-based vectors. Thus, these vectors are useful in discerning the underlying mechanisms of degeneration in diseases where Purkinje cells degenerate, such as the human disorders SCA-2 or SCA-6, or the murine cerebellar degeneration models.

Thus, FIV efficiently transfects Purkinje cells and other cortical neurons and shows promise in correction of cerebellar degeneration both hereditary and acquired.

### EXAMPLE 3

#### TRANSDUCTION OF NEURAL PROGENITOR CELLS

##### USING VIRAL VECTORS

In order to test the ability of various viral vectors to transduce neural progenitor cells the following materials and methods were used.

##### *Neurosphere generation and differentiation*

Progenitor cells from embryonic (day 15-17) mice were obtained essentially as described (Reynolds et al., *J.Neurosci.* 12:4565-4574, 1992). Briefly, embryonic brain was cleared of meninges, diced with a scalpel blade and triturated in Hibernate media (GIBCO, MD) containing 6 g/L total glucose and B27 supplement (GIBCO, MD). Single cells ( $1 \times 10^5$  cells/mL) were cultured in DMEM/F12 containing a final glucose concentration of 6 g/L, ITS supplement (Sigma, St. Louis, MO), 2 mM glutamine, penicillin/streptomycin and 20 ng/mL EGF or 20 ng/mL bFGF (Sigma, St. Louis MO). After 4-7 days and every 4 days subsequent, neurospheres were mechanically dissociated and the media replaced.

For differentiation *in vitro*, neurospheres were plated onto 0.01% polyornithine-coated 24 well plates in DMEM/F12 media containing 6 g/L glucose, 2 mM glutamine, penicillin/streptomycin, 1% FBS and either B27 supplement (Brewer et al., *J.Neurosci.Res.* 35:567-576, 1993) or IGF-1 (20 ng/mL; Sigma, St. Louis, MO).

### *Viral constructs*

Adenoviral vectors expressing either *eGFP* or nuclear targeted  $\beta$ -galactosidase in E1 were produced using the RAPAd™.I system (Anderson et al., *Gene Ther.* 7:1034-1038, 2000). FIV constructs were made by cloning cytoplasmic  $\beta$ -galactosidase or *eGFP* sequences into the pVETLRmcs plasmid (Johnston et al. *J.Virol.* 73:4991-5000, 1999). The resulting plasmids were co-transfected with pCFIV $\Delta$ orf $\Delta$ vif and pCMV.G (Yee et al., *PNAS.* 91:9564-9568, 1994) into HT1080 cells. Viral particles were collected from the media over 4 days and centrifuged at 7500 x G to concentrate particles. Viral particles were resuspended in 40mg/mL lactose in PBS. Recombinant AAV vectors based on AAV2, 4 or 5 were prepared as previously described (Chiorini et al., *J.Virol.* 73:4293-4298, 1999; Chiorini et al., *Hum.Gene Ther.* 6:1531-1541, 1995). Adenoviral and AAV transgenes were under the control of the Rous sarcoma virus LTR promoter (RSVp). FIV constructs contained the cytomegalovirus promoter (CMV).

### *Viral infection of neurospheres*

Neurospheres in EGF or bFGF- containing media (passage number 3-6) were infected with FIV (MOI 0.1 –0.5) or adenovirus (MOI 20) expressing  $\beta$ -galactosidase or *eGFP* in a small volume (200 spheres/500  $\mu$ L media). Samples of neurosphere preparations were dissociated to estimate cell numbers for MOI calculations. After 18 h or 1 h respectively the media was changed and 10 mL added. Expression was monitored over time in EGF-containing media, or neurospheres were differentiated 5 days post infection.

### *Animals and injections*

Six week old C57Bl/6 mice were purchased from Jackson Laboratories (Bar Harbor, MN) and housed at the University of Iowa Animal Care Facility. All animal procedures were approved by the University of Iowa Animal Care and Use Committee. Neurospheres were infected with FIV $\beta$ gal as described above at least 2 weeks prior to transfer into the mouse CNS. Neurospheres were dissociated with a single pass through a 23 gauge needle and approximately 100,000 cells were injected into the striatum (bregma

+ 0.4 mm rostral, 2 mm lateral, at a depth of 3 mm). For tumor-induced migration studies, animals were injected with 100,000 rat C6 tumor cells (ATCC, Manassas, VA) either 15 weeks after or 3 days prior to progenitor cell injection to create an acute injury model (Benedetti et al., *Nat.Med.* 6:447-450, 2000; Herrlinger et al., *Mol.Ther.* 1:347-357). Ten days, 10 weeks, or 15 weeks after injection, animals were perfused with 2% paraformaldehyde and processed as previously described (Ghodsi et al., *Hum.Gene Ther.* 9:2331-2340, 1998) for X gal histochemistry or immunocytochemistry.

#### *Immunocytochemistry*

For cell-type analysis the following antibodies were used; mouse monoclonal glial fibrillary acidic protein (GFAP; 1:3000) conjugated to Cy3, mouse monoclonal MAP2 (1:250;), CNPase (1:1000; Sigma Immunochemicals, St Louis, MO) and rabbit polyclonal  $\beta$ -galactosidase (1:1500; BioDesign International, Saco, MN). Rat 401 which recognizes the progenitor marker, nestin, was obtained from the Developmental Hybridoma Bank, University of Iowa and used at 1:5. Secondary antibodies were goat anti-rabbit or mouse Alexa 488 (Molecular Probes, Eugene, OR), or goat anti-mouse Rhodamine X (Jackson ImmunoResearch, West Grove, PA).

All antibodies were diluted in 3% BSA, 0.1% saponin, 0.3% Triton X-100 in PBS (diluent). After blocking tissues or cells for 30 minutes in diluent containing 10% goat serum, samples were incubated with primary antibodies overnight at 4°C. Sections were washed extensively in diluent and stained with fluorescently-labeled secondary antibodies for 2 h at room temperature. Photomicrographs were captured using Adobe Photoshop and a SPOT/RT digital camera (Diagnostic Inst. Sterling Heights, MI) on a Leiciz DMRBE upright microscope or Olympus IX70 inverted microscope. For colocalization studies, samples were analyzed on a Zeiss LSM confocal microscope and associated software.

### EXAMPLE 3A

#### NEUROSPHERE GENERATION

Neural progenitors were isolated from embryonic day 15-17 mouse brain and maintained in EGF or bFGF-containing media as described above. Earlier work showed that cells propagated in EGF or bFGF have stem cell characteristics, are self-renewing and are multipotent. Over 7-10 days, single cells formed neurospheres in suspension. Cells within the neurospheres expressed the progenitor cell marker, neuroepithelial stem cell intermediate filament ("nestin").

Neurospheres differentiated *in vitro* into neurons, astrocytes and oligodendrocytes with removal of the mitogen and addition of a substrate as previously described (Reynolds et al. *Science* 255:1707-1710, 1992). In contrast to neurospheres differentiated in the presence of growth factors such as IGF-1 or BDNF, spheres differentiated in 1% serum plus B27 supplement had reduced astrocyte migration without similar effect on neurons. In B27 supplemented media neurons migrated beyond the glial border similarly to neurons generated by culture in BDNF or IGF-1.

### EXAMPLE 3B

#### ABILITY OF ADENOVIRAL VECTORS TO INDUCE ASTROCYTE

#### DIFFERENTIATION WITHIN NEUROSPHERES

In order to test the ability of adenoviral vectors to transduce neurospheres and induce astrocyte differentiation, the following experiment was conducted. Adenoviral vectors infect glia and neurons by retrograde transport in the CNS (Davidson et al., *Nat.Genet.* 3:219-223, 1993; Mastrangeli et al., *Clin.Res.* 41:223A(Abstract), 1993; Ghadge et al., *Gene Ther.* 2:132-137, 1995). Recombinant adenovirus (MOI 1 or 20) was used to infect cells within neurospheres, as described above. Transgene expression was observed within 16 h of infection, using the eGFP reporter and maintained for at least 1 month (last time point tested). Within 7 days an apparent change in morphology of transduced cells was seen, concomitant with an increase in GFAP expression, indicating that adenoviral infection induced astrocytic differentiation of progenitor cells. Analysis of neurospheres or cryosections stained for nestin and GFAP confirmed the loss of nestin

and gain of GFAP expression. Differentiation of Ad-infected neurospheres showed that the majority of transduced cells were immunopositive for GFAP and not MAP2.

Thus, recombinant adenovirus resulted in premature differentiation of neural progenitor cells into astrocytes, even in the presence of EGF. Glial processes became  
5 evident between 5 and 7 days after infection. Several studies have reported adenoviral infection of neural progenitor cells in monolayer culture prior to transplantation. Cortis et al., *Nat Biotechnol* 17:349-354, 1999, showed that human neural progenitors infected at a similar MOI to this study, could express a gene product after transplantation to the rat striatum. This study did not address the differentiation of these cells either *in vivo* or *in*  
10 *vitro*. Brüstle et al., *Nat Biotechnol* 16:1040-1044, 1998, showed that Ad-infected human neural progenitors transplanted into embryos 24 h after infection could differentiate into neurons. Similarly, Gage et al., *PNAS* 92:11879-11883, 1995 showed *in vivo* differentiation of Ad-infected rat progenitor cells transplanted into the adult rat hippocampus. Again transplants were performed 24 h post infection. These results  
15 combined with the current study suggest that adenovirus can infect neural progenitor cells. Over time in culture, infection induces differentiation. The presence of adenoviral genes especially those remaining in E4 such as orf 6 may induce differentiation by inhibiting cell division (Goodrum et al, *J.Virol.* 73:7474-7488, 1999). To test this hypothesis, adenoviral constructs devoid of E4 sequences are tested for their effects on  
20 progenitor differentiation.

### EXAMPLE 3C

#### ABILITY OF AAV VECTORS TO TRANSDUCE NEUROSPHERES

AAV2, 4 and 5 have previously been shown to infect differentiated cells in the  
25 CNS, predominantly neurons (McCown et al., *Brain Res.* 713:99-107, 1996; Sutton et al., *J.Virol.* 73:3649-3660, 1999; Davidson et al., *PNAS* 97:3428-3432, 2000; Yandava et al., *PNAS* 96:7029-7034, 1999). These viruses were tested for transduction of neurospheres at MOI of 2. Spheres were maintained for 6 days and differentiated or analyzed for transgene expression after 6 further days. AAV2 infected less than 0.01 % of cells, while  
30 no transgene positive cells were seen after infection with AAV4 or AAV 5.

Thus, none of the AAV serotypes significantly infected any cells within the neurospheres cultured in the presence of EGF. The lack of infection may be due to viral receptor competition with media components or the lack of appropriate receptors. Alternatively, the extracellular matrix components of the neurospheres may interfere with viral uptake.

AAV2 has been shown to require heparin sulfate proteoglycan for infection and uses the fibroblast growth factor receptor and  $\alpha v\beta 5$  integrin as co-receptors (Qing et al., *Nat.Med.* 5:71-77, 1999; Summerford et al., *Nat.Med.* 5:78-82, 1999). Although the receptors for AAV4 and AAV5 are unknown they are insensitive to heparin and differentially infect several cell lines and CNS cell types (Davidson et al., *PNAS* 97:3428-3432, 2000; Alisky et al., *NeuroReport* 11:2669-2673, 2000).

### EXAMPLE 3D

#### ABILITY OF FIV VECTORS TO TRANSDUCE NEUROSPHERES

In order to test the ability of FIV vectors to transduce neurospheres, the following experiment was conducted. FIVEGFP was used at an MOI of 0.1–0.5 and transgene expression monitored as described above. Expression was detectable by 24 h and persisted to at least 28 days (last time-point tested). In order to confirm that a nestin-positive, self-renewing population of progenitor cells were infected by FIV, neurospheres were dissociated into single cells prior to infecting with FIV $\beta$ gal. Regeneration of neurospheres was monitored over 7 days, and cryosections stained for nestin, GFAP, MAP2 and  $\beta$ -galactosidase. Few glial and no neuronal profiles were noted. No qualitative difference was seen in nestin expression between infected and non-infected neurospheres. The majority of cells were nestin-positive, and spheres were either completely positive or completely negative for  $\beta$ -galactosidase. These results indicate that FIV did not prevent self-renewal or progenitor cell maintenance. The lack of detected mosaics (negative and positive cells with an individual sphere) confirmed the clonal derivation of the neurospheres.

To assess the effect of FIV infection on progenitor differentiation, FIV-infected neurospheres were differentiated in B27 or IGF1-containing media, 5 days post-infection.

Both astrocytes and neurons expressed  $\beta$ -galactosidase as seen morphologically by Xgal histochemistry. Cell types were confirmed using immunocytochemistry as described above. Dual labeling with antibodies against  $\beta$ -galactosidase and MAP2 or GFAP confirmed that both neurons and glia could be derived from rFIV transduced progenitor cells.

### EXAMPLE 3E

#### ENGRAFTMENT AND DIFFERENTIATION POTENTIAL OF FIV-INFECTED NEUROSPHERES

FIV $\beta$ gal infected neurospheres were tested *in vivo* for engraftment and differentiation potential. Neurospheres were infected and maintained *in vitro* for 15 days prior to transplant, to reduce the possibility of free virus being carried over into the transplanted brain and infecting host parenchyma. The spheres were dissociated and stereotactically injected into the striatum of normal C57Bl/6 mice and sacrificed at 10 days or 10 or 15 weeks.

After 10 days *in vivo*  $\beta$ -galactosidase positive cells were found in the striatum with scattered cells located in the needle tract and along the corpus callosum. A similar distribution was shown at 10 and 15 weeks. While the progenitor cells apparently lost nestin expression, there was little differentiation into neurons or glia as assessed by NeuN and GFAP immunocytochemistry. Migration of cells was evaluated through the rostral caudal extent of the brain. Neurosphere-derived cells cultured in EGF or bFGF containing maintenance media were found up to 800  $\mu$ m from the injection site in the rostral-caudal direction. Along the corpus callosum cells migrated up to 1 mm from the position of the needle tract.

### EXAMPLE 3F

#### LESION-INDUCED CELL MIGRATION

To examine the effect of rFIV-mediated gene transfer on the *in vivo* migratory potential of neural progenitor cells, a well established model was used (Benedetti et al., *Nat.Med.* 6:447-450, 2000; Aboody et al., *PNAS* 97:12846-12851, 2000). A tumor cell



line, C6, was injected into the contralateral hemisphere from which FIV $\beta$ gal-infected neurospheres were implanted 15 weeks before or 3 days after. One week later the mice were sacrificed and analyzed for tumor cell growth and progenitor cell migration. The tumor cells were immunoreactive for rat IgG and negative for GFAP labeling. Reactive astrocytosis was evident around the lesion site. Sections stained for  $\beta$ -galactosidase showed that in the absence of a tumor, cells remained around the injection site as described above.  $\beta$ -galactosidase labeled progenitor cells in mice injected with tumors were no longer found in the injected hemisphere but rather in the contralateral hemisphere within the tumor mass. Thus, rFIV-transduced progenitor cells retained migratory ability with the injured CNS.

To the best of the inventors' knowledge, this is the first study describing FIV-mediated gene delivery to primary neural progenitor cells. Recombinant FIV pseudotyped with the VSV-G envelope transduced nestin positive neural progenitor cells and did not affect their potential for self-renewal or differentiation into neurons or glia *in vitro*. These cells also retained the capacity to migrate into injured regions as described for mouse C17.2 neural cell lines (Herrlinger et al., *Mol. Ther.* 1:347-357; Snyder et al., *PNAS* 94:11663-11668, 1997), a rat cell line (Benedetti et al., *Nat. Med.* 6:447-450, 2000), and primary mouse neurospheres transduced with a retrovirus (Benedetti et al., *Nat. Med.* 6:447-450, 2000). The lack of significant differentiation of FIV-infected progenitors after striatal injection is similar to previously published results where differentiation is limited in the adult striatum/corpus callosum (Gage et al., *PNAS* 92:11879-11883, 1995). Any differentiation in this region is predominantly glial (Gage et al., *PNAS* 92:11879-11883, 1995), unless cells are injected at a stage where neurogenesis is occurring.

Accordingly, lentiviral vectors and methods of using the same for transducing neural cells, as well as for the treatment of brain disorders have been disclosed. From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the appended claims.

Claims:

1. Use of a lentiviral vector particle for the manufacture of a composition for transducing a neural cell selected from the group consisting of a cerebellar neuron and a neural progenitor cell, wherein said vector particle is produced from a lentiviral vector comprising a 5' lentiviral LTR, a tRNA binding site, a packaging signal, a promoter operably linked to a polynucleotide encoding a protein of interest, an origin of second strand DNA synthesis and a 3' lentiviral LTR.

2. The use of claim 1, wherein said lentiviral vector comprises 5' and/or 3' LTRs from a virus selected from the group consisting of HIV, HIV-1, HIV-2, FIV and SIV.

3. The use of claim 2, wherein said lentiviral vector comprises 5' and/or 3' LTRs from FIV.

4. The use of claim 1, wherein said neural cell is a cerebellar neuron.

5. The use of claim 4, wherein said cerebellar neuron is a Purkinje cell.

6. The use of claim 4, wherein said cerebellar neuron is transduced *in vivo* in a vertebrate subject in need of treatment of a disease that causes cerebellar degeneration.

7. The use of claim 4, wherein said cerebellar neuron is transduced *ex vivo* and the transduced neuron is introduced into a vertebrate subject in need of treatment of a disease that causes cerebellar degeneration.

8. The use of claim 1, wherein said neural cell is a neural progenitor cell.

9. The use of claim 8, wherein said neural progenitor cell is transduced *in vivo* in a vertebrate subject in need of treatment of a central nervous system disorder.

10. The use of claim 8, wherein said neural progenitor cell is transduced *ex vivo* and the transduced cell is introduced into a vertebrate subject in need of treatment of a central nervous system disorder.

5 11. Use of an FIV vector particle for the manufacture of a composition for transducing cerebellar neurons, wherein said vector particle is produced from an FIV vector comprising a 5' FIV LTR, a tRNA binding site, a packaging signal, a polynucleotide encoding a protein of interest operably linked to an FIV LTR promoter or a promoter element, an origin of second strand DNA synthesis and a 3' FIV LTR.

10 12. The use of claim 11, wherein the promoter is a CMV, RSV or SV40 promoter.

13. The use of claim 11, wherein said cerebellar neuron is transduced *in vivo* in a  
15 vertebrate subject in need of treatment of a disease that causes cerebellar degeneration.

14. The use of claim 11, wherein said cerebellar neuron is transduced *ex vivo* and the transduced cerebellar neuron is introduced into a vertebrate subject in need of treatment of a disease that causes cerebellar degeneration.

20 15. Use of an FIV vector particle for the manufacture of a composition for transducing neural progenitor cells, wherein said vector particle is produced from an FIV vector comprising a 5' FIV LTR, a tRNA binding site, a packaging signal, a polynucleotide encoding a protein of interest operably linked to an FIV LTR promoter or  
25 a promoter element, an origin of second strand DNA synthesis and a 3' FIV LTR.

16. The use of claim 15, wherein the promoter is a CMV, RSV or SV40 promoter.

17. The use of claim 15, wherein said neural progenitor cell is transduced *in vivo* in a vertebrate subject in need of treatment of a central nervous system disorder.

5 18. The use of claim 15, wherein said neural progenitor cell is transduced *ex vivo* and the transduced cell is introduced into a vertebrate subject in need of treatment of a central nervous system disorder.

10 19. Use of a lentiviral vector particle for the manufacture of a composition for treating or preventing cerebellar neuronal degeneration or a central nervous system disorder in a vertebrate subject, wherein said vector particle is produced from a lentiviral vector comprising a 5' lentiviral LTR, a tRNA binding site, a packaging signal, a promoter operably linked to a polynucleotide encoding a protein of interest, an origin of second strand DNA synthesis and a 3' lentiviral LTR.

15 20. Use of an FIV vector particle for the manufacture of a composition for treating or preventing cerebellar neuronal degeneration or a central nervous system disorder in a vertebrate subject, wherein said vector particle is produced from an FIV vector comprising a 5' FIV LTR, a tRNA binding site, a packaging signal, a polynucleotide encoding a protein of interest operably linked to an FIV LTR promoter or  
20 a promoter element, an origin of second strand DNA synthesis and a 3' FIV LTR.

21. A method for transducing a neural cell selected from the group consisting of a cerebellar neuron and a neural progenitor cell, said method comprising:

25 (a) providing a lentiviral vector particle, wherein said vector particle is produced from a lentiviral vector comprising a 5' lentiviral LTR, a tRNA binding site, a packaging signal, a promoter operably linked to a polynucleotide encoding a protein of interest, an origin of second strand DNA synthesis and a 3' lentiviral LTR; and

(b) administering said lentiviral vector particle to the neural cell under conditions whereby the protein encoded by the polynucleotide is expressed to produce a transduced  
30 neural cell.

22. A method for transducing a neural cell selected from the group consisting of a cerebellar neuron and a neural progenitor cell, said method comprising:

(a) providing an FIV vector particle, wherein said vector particle is produced from an FIV vector comprising a 5' FIV LTR, a tRNA binding site, a packaging signal, a polynucleotide encoding a protein of interest operably linked to an FIV LTR promoter or a promoter element, an origin of second strand DNA synthesis and a 3' FIV LTR; and

(b) administering said FIV vector particle to the neural cell under conditions whereby the protein encoded by the polynucleotide is expressed to produce a transduced neural cell.

23. A method of treating or preventing cerebellar neuronal degeneration in a vertebrate subject, comprising administering to the subject a lentiviral vector particle, wherein said vector particle is produced from a lentiviral vector comprising a 5' lentiviral LTR, a tRNA binding site, a packaging signal, a promoter operably linked to a polynucleotide encoding a protein of interest, an origin of second strand DNA synthesis and a 3' lentiviral LTR.

24. A method of treating or preventing cerebellar neuronal degeneration in a vertebrate subject, comprising administering to Purkinje cells of the subject an FIV vector particle, wherein said vector particle is produced from an FIV vector comprising a 5' FIV LTR, a tRNA binding site, a packaging signal, a polynucleotide encoding a protein of interest operably linked to an FIV LTR promoter or a promoter element, an origin of second strand DNA synthesis and a 3' FIV LTR.

25. A method of treating or preventing a central nervous system disorder in a vertebrate subject, comprising administering to the subject a lentiviral vector particle, wherein said vector particle is produced from a lentiviral vector comprising a 5' lentiviral LTR, a tRNA binding site, a packaging signal, a promoter operably linked to a

polynucleotide encoding a protein of interest, an origin of second strand DNA synthesis and a 3' lentiviral LTR.

26. A method of treating or preventing a central nervous system disorder in a  
5 vertebrate subject, comprising administering transduced neural progenitor cells  
intraventricularly to the subject, wherein said neural progenitor cells have been  
transduced with an FIV vector particle, wherein said vector particle is produced from an  
FIV vector comprising a 5' FIV LTR, a tRNA binding site, a packaging signal, a  
polynucleotide encoding a protein of interest operably linked to an FIV LTR promoter or  
10 a promoter element, an origin of second strand DNA synthesis and a 3' FIV LTR.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
6 December 2001 (06.12.2001)

PCT

(10) International Publication Number  
**WO 01/091801 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 48/00**,  
C12N 15/867, A61P 25/28, 25/14, 25/16

(21) International Application Number: PCT/US01/17209

(22) International Filing Date: 25 May 2001 (25.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/207,541 26 May 2000 (26.05.2000) US  
60/279,035 27 March 2001 (27.03.2001) US

(71) Applicants (*for all designated States except US*): **CHIRON CORPORATION** [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US). **UNIVERSITY OF IOWA RESEARCH FOUNDATION** [US/US]; 100 Oakdale Campus, #214 TIC, Iowa City, IA 52240 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DAVIDSON, Beverly, L.** [US/US]; 3640 Johnston Way, N.E., North Liberty, IA 52317 (US). **ALISKY, Joseph, M.** [US/US]; 35 Valley Avenue, Apartment 8, Iowa City, IA 52242 (US).

**DUBENSKY, Thomas, W., Jr.** [US/US]; 6 Pacific Avenue, Piedmont, CA 94611 (US). **HUGHES, Stephanie, M.** [NZ/US]; 182 Westside Drive, Apartment 8, Iowa City, IA 52246 (US). **JOLLY, Douglas** [GB/US]; 382 Sunset Drive, Encinitas, CA 92024 (US). **SAUTER, Sybille, L.** [DE/US]; 639 Stratford Court, #17, Del Mar, CA 92014 (US).

(74) Agents: **DOLLARD, Anne**; Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA 94662 et al. (US).

(81) Designated States (*national*): CA, JP, US.

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

Published:

— with international search report

(88) Date of publication of the international search report:  
6 February 2003

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHODS OF TRANSDUCING NEURAL CELLS USING LENTIVIRUS VECTORS

(57) Abstract: Lantivirus gene delivery vectors, such as, for example, recombinant FIV vectors, and methods of using such vectors are provided for use in transducing neural cells, such as neural progenitor cells, and cerebellar neurons, in particular, Purkinje cells.



WO 01/091801 A3

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 01/17209

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K48/00 C12N15/867 A61P25/28 A61P25/14 A61P25/16

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, EMBASE, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 00 66759 A (CELL GENESYS INC.) 9 November 2000 (2000-11-09) claims 1-7 page 22, line 23 - line 26	1-4, 19, 21, 25
X	WO 99 36511 A (CHIRON CORPORATION) 22 July 1999 (1999-07-22) cited in the application  page 40, line 10 - line 12 page 52, line 29 claims 1-51	1-4, 11, 12, 15, 16, 19, 21, 22, 25, 26
X	WO 99 31251 A (CELL GENESYS INC) 24 June 1999 (1999-06-24) claims 1-18 page 10, line 27 - line 33	1-4, 19, 21, 25

-/-



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

25 July 2002

Date of mailing of the international search report

02/08/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Siatou, E



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/JS 01/17209

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 12314 A (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES) 26 March 1998 (1998-03-26) claims 1-28 page 23, line 1 - line 15 page 22, line 9 - line 21 page 21, line 29 -page 22, line 1 ---	1-4, 19, 21, 25
X	WO 98 39463 A (ÜBERLA, KLAUS) 11 September 1998 (1998-09-11)  claims 1-20 ---	1-4, 11, 12, 15, 16, 19, 21, 22, 25, 26
X	WO 97 12622 A (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES) 10 April 1997 (1997-04-10) page 11, line 24 -page 13, line 16 claims 1-22 ---	1-4, 19, 21, 25
X	MITROPHANOUS K A ET AL: "STABLE GENE TRANSFER TO THE NERVOUS SYSTEM USING A NON-PRIMATE LENTIVIRAL VECTOR" GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 6, no. 11, 1999, pages 1808-1818, XP000914884 ISSN: 0969-7128 the whole document ---	1-4, 21
X	BLOMER U ET AL: "HIGHLY EFFICIENT AND SUSTAINED GENE TRANSFER IN ADULT NEURONS WITH A LENTIVIRUS VECTOR" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 71, no. 9, September 1997 (1997-09), pages 6641-6649, XP000826573 ISSN: 0022-538X abstract page 6647, left-hand column, last paragraph -page 6648, left-hand column ---	1-4
X	NALDINI ET AL: "Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, no. 21, 15 October 1996 (1996-10-15), pages 11382-11388, XP002114690 ISSN: 0027-8424 the whole document ---	1-4

-/--

# INTERNATIONAL SEARCH REPORT

h onal Application No

rci/US 01/17209

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>NALDINI L ET AL: "IN VIVO GENE DELIVERY AND STABLE TRANSDUCTION OF NONDIVIDING CELLS BY A LENTIVIRAL VECTOR"</p> <p>SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US,</p> <p>vol. 272, no. 5259,</p> <p>12 April 1996 (1996-04-12), pages 263-267, XP000583652</p> <p>ISSN: 0036-8075</p> <p>page 265, right-hand column, line 14 -page 266, middle column</p> <p>-----</p>	1-4

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/17209

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 23-26 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/17209

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0066759	A	09-11-2000	AU 4489700 A EP 1171624 A1 WO 0066759 A1	17-11-2000 16-01-2002 09-11-2000
WO 9936511	A	22-07-1999	US 2002048805 A1 AU 2329599 A CA 2318575 A1 EP 1045921 A2 WO 9936511 A2 US 2002068354 A1	25-04-2002 02-08-1999 22-07-1999 25-10-2000 22-07-1999 06-06-2002
WO 9931251	A	24-06-1999	US 5994136 A AU 1803499 A CA 2314609 A1 EP 1036182 A1 JP 2002508184 T WO 9931251 A1 US 6165782 A	30-11-1999 05-07-1999 24-06-1999 20-09-2000 19-03-2002 24-06-1999 26-12-2000
WO 9812314	A	26-03-1998	AU 4261797 A EP 0970201 A1 JP 2001501815 T WO 9812314 A1	14-04-1998 12-01-2000 13-02-2001 26-03-1998
WO 9839463	A	11-09-1998	AU 7332198 A WO 9839463 A2 EP 0991771 A2 JP 2001513643 T	22-09-1998 11-09-1998 12-04-2000 04-09-2001
WO 9712622	A	10-04-1997	US 6013516 A AU 720993 B2 AU 7168196 A EP 0871459 A1 JP 11512615 T WO 9712622 A1 ZA 9608382 A	11-01-2000 22-06-2000 28-04-1997 21-10-1998 02-11-1999 10-04-1997 27-06-1997